Aradigm (ARDMQ) Stock Price, News & Analysis

Company Overview

Aradigm Corporation, trading under the ticker ARDMQ on the OTC Markets, is a clinical‐stage specialty biopharmaceutical company dedicated to the development and commercialization of inhaled therapies for the treatment of pulmonary and infectious diseases. Founded in 1992 and headquartered in Hayward, California, Aradigm has built its research platform around proprietary aerosol delivery technologies, including the AERx inhalation system originally engineered for precision dosing of therapeutic agents to the respiratory tract.

The company’s lead product candidate, Pulmaquin (ciprofloxacin inhalation powder), is designed to treat chronic Pseudomonas aeruginosa infections commonly associated with non–cystic fibrosis bronchiectasis. Pulmaquin has completed multiple Phase 2 and Phase 3 clinical trials in the United States and Europe, evaluating safety, tolerability and efficacy in adults with bronchiectasis. In addition to Pulmaquin, Aradigm is advancing an early‐stage pipeline that leverages its ExoSphere™ technology to improve targeted delivery of small molecules and biologics to deep lung tissues.

Aradigm’s clinical development programs are supported by a management team with extensive experience in respiratory drug development and regulatory strategy. The company collaborates with contract research organizations and academic centers across North America and Europe to conduct its trials, and it maintains strategic partnerships to expand the reach of its aerosol delivery platform. Aradigm continues to explore opportunities to divest or partner selected assets while pursuing regulatory approvals for its inhaled therapies.

Key Stats

• Today's Range: $0.05 to $0.05
• 50-Day Range: $0.05 to $0.05
• 52-Week Range: $0.02 to $0.20
• Volume: N/A
• Average Volume: 21,923 shs
• Market Capitalization: $764 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Today: 6/26/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Electromedical Equipment
• Sub-Industry: Medical Equipment
• Current Symbol: OTCMKTS:ARDMQ
• CIK: N/A
• Web: www.aradigm.com
• Phone: 510-265-9000
• Fax: 510-265-8878
• Employees: 23
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 15,280,000
• Free Float: N/A
• Market Cap: $764 thousand
• Optionable: Not Optionable
• Beta: N/A